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Background: The purpose of this prospective study is to investigate the discrepancy
in the volume of shrinkage of uterine fibroids after treatment with gonadotropin
releasing hormone analogs (GnRHa).
Materials and Methods: Twenty-one patients, who were diagnosed as having
a single uterine fibroid before any further intervention, were included. They received
myomectomy after two complete doses of leuprorelin acetate 3.75 mg (Leuplin
Depot), a GnRHa injected subcutaneously at an interval of 4 weeks. The vascularization
index, flow index, vascularization–flow index, pulsative index, resistance index,
vascular patterns (histogram), blood flows and sizes (volume and largest diameter)
of each fibroid were measured with power Doppler every month before the operation.
Results: The mean volume of the pre-treated uterus and the fibroid was
473.8 cm3 and 302.4 cm3, respectively. The mean decrease in the volume of the
uterus and the fibroid was 97.3 cm3 and 68.3 cm3, respectively. Fourteen patients
had a significant decrease in the volume of the post-treated fibroid (mean percentage
of decrease in volume was 43%). The decrease in volume was significant when
the pre-treated fibroid volume was above 200 cm3.
Conclusions: From these results, the trend suggests that the larger the fibroid
(> 200 cm3), the greater the decrease in volume after treatment. The discrepancy
in the volume of shrinkage of the fibroids may be due to their heterogenicity, which
should be further investigated in the future.
(J Med Ultrasound 2004;12:114–8)
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INTRODUCTION
Uterine fibroid is the most common benign
gynecologic tumor, which accounts for more than
80% of gynecologic operations. In order to preserve
the uterus, the combination of medical and surgical
management, such as treatment with gonadotropin
releasing hormone analogs (GnRHa) before the
operation, had been suggested. We aimed to determine
the clinical and histologic effects of GnRHa on
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uterine leiomyoma. The shrinkage of the volume of
fibroids is always the main focus for medical
treatment, and the main purpose of this study was
to use the novel technique of three-dimensional
ultrasound to evaluate the effectiveness of medical
treatment before the operation.
MATERIALS AND METHODS
We enrolled 21 patients who had uterine fibroids,
with or without clinical symptoms, for this prospective
study. Each subject received three-dimensional power
Doppler ultrasound before medication and surgery
for the following parameters: (1) fibroid: size, volume
and blood flow patterns in histogram such as
vascularization index (VI), flow index (FI) and
vascularization–flow index (VFI); (2) uterus: blood
flow in the uterine arteries in pulsative index (PI)
and resistance index (RI). All of these ultrasonic
measurements were collected and analyzed through
Medison 530D (Medison, Seoul, Korea), a three-
dimensional ultrasound, by the same technician.
Three months before the operation, each patient
was given two consecutive doses of leuprorelin
acetate Depot 3.75 mg (Leuplin Depot), a GnRHa
agent, injected subcutaneously (SC) at an interval
of 4 weeks, and the operation was performed at the
end of the third month after the first injection. All
the GnRHa agents were supplied by Takeda Chemical
Industries (Taiwan), Ltd (Taipei, Taiwan).
The schedule of ultrasounds performed on the
patients were: (a) before each injection, (b) before
the surgery, and (c) 3 consecutive months after
surgery. All of the data were collected and analyzed.
RESULTS
Twenty-one patients were enrolled in this study.
They received ultrasound before each injection, before
the operation and for 3 consecutive months after the
operation. The data obtained after the experiment
included: (1) mean age (34.8 yrs, 27–45 yrs; (2)
mean percentage of decrease in fibroid volume (43%);
(3) mean difference in PI (0.19, p = 0.43); (4) mean
difference in RI (0.01, p = 0.87); (5) mean difference
in VI (–4.05, p = 0.09); (6) mean difference in FI
(–2.42, p = 0.36); (7) mean difference in VFI
(–4.36, p = 0.04).
There was a significant decrease in uterine
and fibroid volume but not in the vascularity (Tables
1–3). The disproportional changes between the uterine
and the fibroid volume in some cases may have been
due to genetic and histologic discrepancies (Table
3).
DISCUSSION
Uterine fibroids are the most common benign
neoplasm in the female pelvis, and occur in 20–25%
of women of reproductive age. They arise mostly
from the smooth muscle and soft tissue of the uterine
fundus and corpus, but 3% arise in the cervix [1].
Various methods of management, including non-
surgical methods such as treatment with GnRHa,
progesterone or danazol, and surgical methods such
as hysterectomy, myomectomy, or obliteration of
uterine arteries, have been indicated. The present
study was designed to evaluate the response of
fibroids in several aspects, especially the vascularity
after GnRHa treatment.
There are several effects of GnRHa on fibroids.
Histologically, the arterioles in myomas have
significantly thicker walls, which is due to smooth
muscle cell hyperplasia in the muscularis media,
which may play a role in the decreased flow of blood
[2]. Intramyomatous arteries are smaller, and have
often shown arteriosclerotic changes in the
leiomyomas that were removed from women treated
with GnRHa. The estrogen deprivation induced by
GnRHa may cause a relative vasoconstriction of
myomatous vessels. Increased cellularity and
hyalinization in leiomyomata follows GnRH-agonist
treatment. GnRHa therapy suppresses cell
proliferation and causes a transient increase in
apoptosis in uterine leiomyomas [3].
Additionally, the cellular proliferation index, ER,
PR expression and the number of cycling cells
decreases, which is a relative overexpression of both
collagen type I and collagen type III mRNAs [4].
In our study, the vascularization on the periphery
of the myoma with an RI of 0.54 ( 0.08 showed
better delineation, but, for the others myomas, such
as necrosis, inflammation or degenerative change,
there was a lower RI. Furthermore, the uterine arteries
in those who have myoma showed a lower impedance
(RI = 0.74 ( 0.09) than those without a myoma
(RI = 0.84 ( 0.09) [5]. From the use of three-
dimensional power Doppler, a regular vascularity at
the periphery was detected in 84.3% of the myomas
[6].
C.C. Chia, S.C. Huang, S.S. Chen, et al
116 J Med Ultrasound 2004 • Vol 12 • No 4
Table 1. Comparison of variables between VI, FI and VFI in fibroids
Patient No. Pre-VI Post-VI Diff-VI Pre-FI Post-FI Diff-FI Pre-VFI Post-VFI Diff-VFI
1 0.007 0.057 0.050 37.600 57.600 20.000 0.002 0.033 0.031
2 25.790 0.700 –25.090 68.700 41.730 –26.970 17.700 0.290 –17.410
3 3.010 2.500 –0.510 43.000 60.480 17.480 32.880 1.560 –31.320
4 1.570 0.780 –0.790 69.230 66.650 –2.580 1.090 0.520 –0.570
5 1.620 1.080 –0.540 64.610 61.780 –2.830 1.050 0.660 –0.390
6 4.170 1.090 –3.080 74.610 70.600 –4.010 3.110 0.770 –2.340
7 3.280 1.010 –2.270 70.470 67.090 –3.380 2.310 0.680 –1.630
8 8.380 21.350 12.970 69.920 71.020 1.100 5.850 15.160 9.310
9 4.140 4.920 0.780 65.050 57.710 –7.340 2.690 2.840 0.150
10 8.420 13.940 5.520 68.100 65.380 –2.720 5.730 9.110 3.380
11 17.130 1.370 –15.760 66.340 65.880 –0.460 11.360 0.900 –10.460
12 15.400 0.350 –15.050 68.230 59.130 –9.100 10.500 0.210 –10.290
13 19.000 0.730 –18.270 70.000 63.650 –6.350 13.300 0.460 –12.840
14 22.700 1.450 –21.250 74.300 46.700 –27.600 16.900 0.670 –16.230
15 11.900 0.530 –11.370 59.630 66.880 7.250 7.150 0.350 –6.80
16 0.610 2.840 2.230 53.880 63.030 9.150 0.330 1.790 1.460
17 0.280 12.420 12.140 61.730 61.720 –0.010 0.170 7.660 7.490
18 2.510 1.730 –0.780 66.350 47.270 –19.080 1.660 0.820 –0.840
19 0.530 1.650 1.120 64.510 66.330 1.820 0.348 1.090 0.742
20 8.700 15.900 7.200 69.820 69.360 –0.460 6.070 11.090 5.020
21 200.000 7.610 –12.390 68.850 74.160 5.310 13.70 5.640 –8.060
Mean –4.050 –2.410 –4.360
SD 10.600 12.890 9.560
p 0.090 0.360 0.049
VI = color voxels/(total voxels–background voxels); FI = weighed color voxels/(color voxels–border voxels); VFI = weighed
color voxels/(total voxels–background voxels); Pre = pretreatment; Post = post-treatment; Diff = differences.
Another new method of vascular quantification,
called three-dimensional histogram, was recently
reported. It measures the color percentage and flow
amplitudes in the volume of interest. Artifacts such
as tissue, patient, or probe movements are still
common because of the high sensitivity of the
amplitude-based color Doppler. The parameters of
three-dimensional histograms are VI, FI, VFI and
flow–vessel quotient. These parameters will provide
the numbers of vessels and the intensity of flow in
the tumor or tissue [7].
If treated leiomyomatas are not surgically removed
immediately after therapy, a rapid regrowth can
occur and there can be a relapse of clinical symptoms.
The volume of fibroids will shrink from 30–40%
after two to three doses of GnRHa, but will bounce
back to the same volume or larger within 2–3 months
after the cessation of the drug. With respect to
vascularity, statistically significant increases in RI
and PI values for major leiomyoma vessels, observed
at the end of the fourth week, increased significantly
after 8 and 12 weeks. These findings were in direct
correlation with a significant decrease of estradiol
levels after 4, 8 and 12 weeks [8].
For the dosages and duration of GnRHa, according
to the literature and the experiences gained, the
volume of the fibroids shrank dramatically [9–11].
There also was decreased total blood loss during the
operation, after two doses of GnRHa injection. Hence,
we used two doses of Leuplin Depot 3.75 mg SC
injection, at a 1-month interval. Myomec-tomy was
performed 1 month after the last dose. An induction
of a higher reduction of fibroid sizes by the
combination of GnRHa with raloxifene was reported.
Conservative management of fibroid, with decreased
morbidity is important, especially in women who
plan to become pregnant.
From our findings, we conclude that the vascularity
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Table 2. Comparison of RI and PI values in the uterine artery
Patient No. Pre-RI Post-RI Diff-RI Pre-PI Post-PI Diff-PI
1 0.78 0.29 –0.49 1.61 3.19 1.58
2 0.12 1.00 0.88 5.40 5.50 0.10
3 0.44 0.25 –0.19 1.48 2.57 1.09
4 0.22 0.39 0.17 0.92 1.07 0.15
5 0.90 1.00 0.10 3.06 2.59 –0.47
6 0.71 0.59 –0.12 1.98 2.51 0.53
7 0.52 0.68 0.16 1.98 1.53 –0.45
8 0.67 0.61 –0.06 1.11 2.23 1.12
9 0.45 0.35 –0.10 1.20 2.78 1.58
10 0.78 1.00 0.22 2.15 2.77 0.62
11 0.74 0.44 –0.30 1.96 1.50 –0.46
12 0.14 0.64 0.50 0.96 2.96 2.00
13 0.67 0.45 –0.22 1.96 2.39 0.43
14 0.81 0.64 –0.17 2.46 1.17 –1.29
15 0.31 0.2 –0.11 1.15 0.98 –0.17
16 0.23 0.69 0.46 3.94 3.05 –0.89
17 0.38 0.29 –0.09 1.35 0.77 –0.58
18 0.88 0.86 –0.02 2.20 3.63 1.43
19 0.80 0.38 –0.42 4.55 2.43 –2.12
20 0.34 0 –0.34 1.11 0 –1.11
21 0.62 1.00 0.38 2.70 3.57 0.87
Mean 0.01 0.18
SD 0.33 0.08
p 0.87 0.43
RI = resistance index; PI = pulsative index; Pre = pretreatment; Post = post-treatment; Diff = differences.
Table 3. The uterine and fibroid volume by ultrasound before and after GnRHa treatment
Patient No. Pre-vol (ut) Post-vol (ut) Diff-ut Pre-vol (F) Post-vol (F) Diff-vol (F)
1 158.7 106.9 –51.8 29.5 10.8 –18.7
2 167.6 133 –34.6 181.9 82.3 –99.6
3 169.7 139.7 –30.0 29.0 27.4 –1.6
4 189.1 195.8 6.7* 98.8 126.9 28.0*
5 201.4 111.0 –90.4 134.62 21.3 –113.3
6 236.5 208.5 –27.9 102.9 107.1 4.3*
7 245.7 111.2 –134.5 126.2 59.1 –67.1
8 281.4 208.6 –72.8 143.8 124.7 –19.1
9 298.8 371.2 72.3* 166.0 181.3 15.3*
10 303.4 289.3 –14.0 208.7 150.3 –58.4
11 351.2 147.2 –204.0 56.6 40.4 –16.2
12 355.3 364.4 9.1* 214.2 165.1 –49.1
13 363.1 365.5 0.4* 269.6 280.7 11.1*
14 372.9 357.3 –15.6 178.4 139.8 –38.6
15 449.7 256.8 –192.9 295.9 109.0 –186.9
16 481.5 309.7 –171.8 329.0 176.7 –152.3
17 561.3 430.9 –130.4 193.0 212.3 19.3*
18 757.5 598.7 –158.8 479.8 335.6 –144.2
19 787.6 859.3 71.7* 450.8 542.7 91.9*
20 971.9 990.3 18.4* 882.1 709.6 –172.5
21 1,613.7 721.5 –892.2 829.7 363.2 –466.5
*The disproportional changes between the uterine and the fibroid volume may be due to the genetic and histologic discrepancies.
GnRHa  = gonadotropin releasing hormone analogs; Pre-vol (ut) = pretreatment uterine volume; Post-vol (ut) = post-treatment
uterine volume; Diff-ut = difference in the uterine volume before and after the treatment; Pre-vol (F) = pretreatment fibroid
volume; Post-vol (F) = post-treatment fibroid volume; Diff-vol (F) = difference in the fibroid volume before and after the treatment.
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of fibroids (including VI, FI, VFI), fibroid volume
and uterine volume decreased after two doses of
GnRHa treatment. Additionally, blood loss during
the operation significantly decreased as compared
with the untreated groups. The quantitative values
(including VI, FI, VFI) of the three-dimensional
histogram were not significantly different, due to the
small number of patients.
We conclude that the discrepancy of fibroid
shrinkage after GnRHa treatment is significantly
indicated when the fibroid volume is more than
200 cm3. Three-dimensional ultrasound is an-
other powerful tool for the measurement of volume
for the pre-operation or conservative treatment of
fibroids.
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